Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
TheBody.com covers the 48th Annual ICAAC/IDSA 46th Annual Meeting; Washington, D.C.; October 25-28, 2008
  • Email Email
  • Glossary Glossary


Clinical Management
Mari Kitahata, M.D., and Daniel Kuritzkes, M.D Starting HAART: Should 500 Become the New 350?
Mari Kitahata, M.D., and Daniel Kuritzkes, M.D., discuss a 5,926-patient trial that found a 74% higher mortality risk among those who deferred HAART until their CD4 dropped below 350 rather than initiating when their CD4 was between 351 and 500. Dr. Kuritzkes also touches on new developments in HIV drug resistance.
Read or listen (35 min.):
More Top Stories:

All Headlines

About This Conference

The Body PRO's coverage of The 48th Annual ICAAC/IDSA 46th Annual Meeting will include a wide array of individual presentations and symposia, as well as summaries of some of the hottest topics in HIV research.

For more information on The 48th Annual ICAAC/IDSA 46th Annual Meeting, please visit the conference's Web site. You may also view the conference program online.


This coverage was provided by The Body. Copyright © Body Health Resources Corporation. All rights reserved.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

  • Email Email
  • Glossary Glossary

Advertisement